Il-Kyu Kim
Overview
Explore the profile of Il-Kyu Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Norgard R, Pitarresi J, Maddipati R, Aiello-Couzo N, Balli D, Li J, et al.
EMBO Rep
. 2021 Jul;
22(9):e51872.
PMID: 34324787
Epithelial plasticity, or epithelial-to-mesenchymal transition (EMT), is a well-recognized form of cellular plasticity, which endows tumor cells with invasive properties and alters their sensitivity to various agents, thus representing a...
12.
Pitarresi J, Norgard R, Chiarella A, Suzuki K, Bakir B, Sahu V, et al.
Cancer Discov
. 2021 Feb;
11(7):1774-1791.
PMID: 33589425
Pancreatic cancer metastasis is a leading cause of cancer-related deaths, yet very little is understood regarding the underlying biology. As a result, targeted therapies to inhibit metastasis are lacking. Here,...
13.
Li J, Yuan S, Norgard R, Yan F, Sun Y, Kim I, et al.
Cancer Discov
. 2020 Nov;
11(3):736-753.
PMID: 33158848
Although immunotherapy has revolutionized cancer care, patients with pancreatic ductal adenocarcinoma (PDA) rarely respond to these treatments, a failure that is attributed to poor infiltration and activation of T cells...
14.
Cho S, Kim S, Lee Y, Song E, Kim U, Kim H, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32461342
Background: The generation of antigen-specific cytotoxic T lymphocyte (CTL) responses is required for successful cancer vaccine therapy. In this regard, ligands of Toll-like receptors (TLRs) have been suggested to activate...
15.
Koh C, Kim I, Shin K, Jeon I, Song B, Lee J, et al.
Cancer Immunol Res
. 2020 Mar;
8(5):698-709.
PMID: 32122993
Although treatment with the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) agonistic antibody (DTA-1) has shown antitumor activity in various tumor models, the underlying mechanism is not fully understood. Here,...
16.
Song B, Lee J, Park Y, Kim I, Kim B, Shin K, et al.
FASEB J
. 2020 Jan;
34(3):4462-4481.
PMID: 31989715
Myeloid progenitor cells have generally been considered the predominant source of myeloid cells under steady-state conditions. Here we show that NK cells contributed to a myeloid cell lineage pool in...
17.
Shin K, Jeon I, Kim B, Kim I, Park Y, Koh C, et al.
Front Immunol
. 2019 Sep;
10:1887.
PMID: 31474983
Monocyte-derived dendritic cells (moDCs) have been shown to robustly expand during infection; however, their roles in anti-infectious immunity remain unclear. Here, we found that moDCs were dramatically increased in the...
18.
Bae E, Seo H, Kim I, Jeon I, Kang C
Arch Pharm Res
. 2019 Mar;
42(7):543-548.
PMID: 30859410
Cancer immunotherapy has emerged as an effective therapeutic strategy to treat cancer. Among diverse immune populations, invariant natural killer T (iNKT) cells have shown potent antitumor activity by linking innate...
19.
Kim I, Koh C, Jeon I, Shin K, Kang T, Bae E, et al.
Cancer Immunol Res
. 2019 Feb;
7(3):498-509.
PMID: 30728152
GM-CSF as an adjuvant has been shown to promote antitumor immunity in mice and humans; however, the underlying mechanism of GM-CSF-induced antitumor immunity remains incompletely understood. In this study, we...
20.
Bae E, Seo H, Kim B, Choi J, Jeon I, Shin K, et al.
Cancer Res
. 2018 Jul;
78(18):5315-5326.
PMID: 30012672
PD-1-based cancer immunotherapy is a successful example of immune checkpoint blockade that provides long-term durable therapeutic effects in patients with cancer across a wide spectrum of cancer types. Accumulating evidence...